340B Orphan Drug Exclusion Seems Untenable, Sen. Hatch Tells HRSA
This article was originally published in The Pink Sheet Daily
Executive Summary
Following the Health Resources and Services Administration’s final rule on excluding orphan drugs from the 340B discount, Sen. Hatch writes to object to the agency’s interpretation of the statutory language.
You may also be interested in...
340B Final Rule Keeps Orphan Drug Exclusion Narrow, Counter To Manufacturers’ Request
HRSA’s final rule on the exclusion of orphan drugs from 340B discounts says the exclusion applies only to the FDA-designated orphan indication, not all uses of a drug with a rare-disease designation.
Senior Senators Seek Details On Government Audits Of 340B Entities
Top Republicans on two Senate health committees are joined by House members in seeking answers on an HHS review of entities receiving 340B drug discounts, including the process and consequences of audits and decertification.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.